Mary Ann Hodorowicz, RD, LDN, MBA, CDE, CEC
Mary Ann Hodorowicz is an RD and CDE and earned her MBA with a focus on marketing. She is also a Certified Endocrinology Coder and owns a private practice specializing in business clients in Palos Heights, Illinois.
She is a consultant, professional speaker, trainer and author for the health, food and pharmaceutical industries in nutrition, wellness, diabetes and Medicare and private insurance reimbursement.
Her clients include healthcare entities, professional membership associations, pharmacies, medical CEU education/training firms, government agencies, food and pharmaceutical companies, academia and employer groups.
She is on the faculty of several train-the-trainer programs, including the Johnson and Johnson Diabetes Institute, Pesi Healthcare, and a pharmacy program for training on DSMT accreditation by AADE, Present Diabetes e-Learning Systems, Balancing Life's Issues, and is on the speaker's bureau of Novartis/Nestle Nutrition, Inc..
Mary Ann has given over 300 professional presentations and webinars for several healthcare organizations and business entities. She has authored several resources, articles and tool kits for the Academy of Nutrition and Dietetics and AADE, has served on the editorial advisory board for AADE in Practice, and has continually served on president-elect committees of the Academy. Mary Ann is on the Board of Directors for AADE.
In her career, she has provided outpatient MNT and DSME, designed a hospital Outpatient Diabetes Center and recognized DSME program and worked as a Clinical Nutrition Manager, Assistant Director of a hospital Food and Nutrition Services Department and an ADA Dietetic Traineeship Director.
Polenta With Parmesan Sausage Lentil Soup Chocolate Cherry Cookies Red Wine Cucumber Salad Asian-Style Pork with Green Soybeans Garlicky Spinach Blueberry Cheese "Danish" Cinnamon-Spiced Pumpkin Soup Mojo-Lime Chicken Rice Pudding
A member of the Digital Diabetes Group on LinkedIn posted a link to an article suggesting that one (currently) off-label use of a specific calcium channel blocker (blood pressure lowering) drug might be to prevent or cure type 1 diabetes. Of course, right now the only study has been in